Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma

被引:0
|
作者
Mahasneh, AA
Abdel-Hafiz, SS
机构
[1] Jordan Univ Sci & Technol, Dept Biotechnol & Genet Engn, Irbid 22110, Jordan
[2] Jordan Univ Sci & Technol, Dept Lab Med Sci, Irbid 22110, Jordan
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine the prevalence of 3 polymorphisms in p53 gene in 3 healthy Jordanian groups and 2 cancer patient groups. Methods: Genomic DNA was extracted from blood samples obtained from 84 cancer patients (breast and lung adenocarcinoma) and 136 healthy subjects (representing Jordanian general population, Bedouins and Charkas). Samples were collected from Al-Amal Hospital for Cancer, Amman and from health centers located in different regions of Jordan from March 2002 to October 2002. Polymerase chain reaction (PCR) was used to amplify intron 3, exon 4 and intron 6 and PCR products were analyzed using gel electrophoresis and BstUl and MspI analysis. Allele frequencies (AI) were estimated for the 3 polymorphisms and Chi-square (chi(2)) test was used to determine the significance of differences from the Hardy-Weinberg equilibrium. Results: Differences in allele frequencies for all 3 polymorphisms were observed among the various groups. Analysis based on haplotype frequencies showed that MspI A2 allele linked to BstUI allele was associated with lung adenocarcinoma, whereas the loss of the 16-bp duplication allele in combination with MspI A2 allele was associated with breast cancer. In the cancer patients, the most frequent extended haplotype was the absence of the 16-bp duplication in combination with the presence of the BstUI A2 and MspI restriction sites. Conclusion: No significant difference was found with respect to the BstUl polymorphism between cancer patients and healthy groups. However, a significant difference was found with respect to the MspI polymorphism between lung adenocarcinoma patients and healthy Jordanian general population. Charkas have a hiolier cancer risk than Jordanian general population based on the (16bp A1-MspI A2) for breast cancer and (MspI A2-BstUI A2) for lung adenocarcinoma.
引用
收藏
页码:1568 / 1573
页数:6
相关论文
共 50 条
  • [1] p53 polymorphism in ovarian and breast cancer
    Campbell, IG
    Eccles, DM
    Dunn, B
    Davis, M
    Leake, V
    LANCET, 1996, 347 (8998): : 393 - 394
  • [2] Is p53 a breast cancer gene?
    Polyak, K
    CANCER BIOLOGY & THERAPY, 2002, 1 (01) : 37 - 38
  • [3] p53 codon 72 polymorphism and the risk of lung cancer in a Korean population
    Piao, Jin-Mei
    Kim, Hee Nam
    Song, Hye-Rim
    Kweon, Sun-Seog
    Choi, Jin-Su
    Yun, Woo-Jun
    Kim, Young-Chul
    Oh, In-Jae
    Kim, Kyu-Sik
    Shin, Min-Ho
    LUNG CANCER, 2011, 73 (03) : 264 - 267
  • [4] Association of p53 Codon 72 Polymorphism with Breast Cancer in a Rwandese Population
    Habyarimana, Thierry
    Attaleb, Mohammed
    Mugenzi, Pacifique
    Mazarati, Jean Baptiste
    Bakri, Youssef
    El Mzibri, Mohammed
    PATHOBIOLOGY, 2018, 85 (03) : 186 - 191
  • [5] Polymorphism of the p53 gene within the codon 72 in lung cancer patients
    Biros, E
    Kalina, I
    Biros, I
    Kohüt, A
    Bogyiová, E
    Salagovic, J
    Stubña, J
    NEOPLASMA, 2001, 48 (05) : 407 - 411
  • [6] The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer
    Lee, JM
    Shun, CT
    Wu, MT
    Chen, YY
    Yang, SY
    Hung, HI
    Chen, JS
    Hsu, HH
    Huang, PM
    Kuo, SW
    Lee, YC
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 594 (1-2) : 181 - 188
  • [7] P53 codon 72 polymorphism in breast cancer
    Buyru, N
    Tigli, H
    Dalay, N
    ONCOLOGY REPORTS, 2003, 10 (03) : 711 - 714
  • [8] Association of P53 codon 72 polymorphism and lung cancer in an ethnic Iranian population
    Eydian, Z.
    Asna'ashari, A. M. H.
    Behravan, J.
    Sharifi-Rad, J.
    Heravi, R. Entezari
    CELLULAR AND MOLECULAR BIOLOGY, 2016, 62 (09) : 34 - 38
  • [9] Possible association of thioredoxin and p53 in breast cancer
    Ueno, M
    Matsutani, Y
    Nakamura, H
    Masutani, H
    Yagi, M
    Yamashiro, H
    Kato, H
    Inamoto, T
    Yamauchi, A
    Takahashi, R
    Yamaoka, Y
    Yodoi, J
    IMMUNOLOGY LETTERS, 2000, 75 (01) : 15 - 20
  • [10] The p53 codon 72 polymorphism and lung cancer risk
    Fan, R
    Wu, MT
    Miller, D
    Wain, JC
    Kelsey, KT
    Wiencke, JK
    Christiani, DC
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2000, 9 (10) : 1037 - 1042